Velikova T, Gulinac M. Urgent need for prognostic markers for hepatocellular carcinoma in the light of genomic instability and non-coding RNA signatures. World J Gastrointest Surg 2024; 16(10): 3087-3090 [PMID: 39575279 DOI: 10.4240/wjgs.v16.i10.3087]
Corresponding Author of This Article
Milena Gulinac, MD, PhD, Academic Research, General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Oct 27, 2024; 16(10): 3087-3090 Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3087
Urgent need for prognostic markers for hepatocellular carcinoma in the light of genomic instability and non-coding RNA signatures
Tsvetelina Velikova, Milena Gulinac
Tsvetelina Velikova, Milena Gulinac, Medical Faculty, Sofia University Street Kliment Ohridski, Sofia 1407, Bulgaria
Milena Gulinac, General and Clinical Pathology, Medical University of Plovdiv, Plovdiv 4002, Bulgaria
Co-first authors: Tsvetelina Velikova and Milena Gulinac.
Author contributions: Velikova T and Gulinac M wrote the paper; Velikova T revised the paper. Both authors approved the final version of the manuscript before submission.
Supported byThe European Union-Next Generation EU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, No. BG-RRP-2.004-0008.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Milena Gulinac, MD, PhD, Academic Research, General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Received: April 8, 2024 Revised: May 12, 2024 Accepted: July 8, 2024 Published online: October 27, 2024 Processing time: 173 Days and 4.6 Hours
Abstract
In this editorial, we comment on an original article by Duan et al. Despite advancements in the diagnosis and treatment of hepatocellular carcinoma (HCC), the identification of suitable prognostic factors remains challenging. In their paper, Duan et al identified long non-coding RNAs (LncRNAs) to quantify genomic instability (GI) by combining LncRNA expression and somatic mutation profiles. They confirmed that the GI-derived LncRNA signature (GI-LncSig) could be an independent prognostic factor with the area under the curve of 0.773. Furthermore, the authors stated that GI-LncSig may have a better predictive performance than TP53 mutation status alone. However, studies exploring genetic markers for predicting the prognosis of HCC are crucial for identifying therapeutic targets and enhancing diagnostic and treatment strategies to mitigate the global burden of liver cancer.
Core Tip: Despite challenges in diagnosing and treating hepatocellular carcinoma (HCC), identifying suitable prognostic factors is crucial. Duan et al proposed a novel approach using long non-coding RNAs (LncRNAs) to quantify genomic instability (GI) in HCC. Their study demonstrated that the GI-derived LncRNA signature is an independent prognostic factor, outperforming TP53 mutation status alone with an area under the curve of 0.773. These findings underscore the importance of exploring genetic markers for predicting HCC prognosis, aiding in identifying therapeutic targets and improving diagnostic and treatment strategies to alleviate the global burden of this disease.
